AMNEAL PHARMACEUTICALS, INC. Other Noncash Income (Expense)
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Other Noncash Income (Expense) of -$3.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2026-06-30 was -$1.60M.
- AMNEAL PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2026-03-31 was -$1.49M.
- AMNEAL PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2025-12-31 was -$1.16M.
- AMNEAL PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2025-09-30 was -$1.32M.
- AMNEAL PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2025 was -$4.73M.
- AMNEAL PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2024 was -$1.52M.
- AMNEAL PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2023 was -$9.92M.
- AMNEAL PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2022 was -$8.83M.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month | Other Noncash Income (Expense) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.09M 10-Q · filed 2026-08-06 | -$4.24M derived: sum of 3 quarters · filed 2026-08-06 | -$5.56M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$1.49M 10-Q · filed 2026-05-07 | -$2.64M derived: sum of 2 quarters · filed 2026-05-07 | -$3.96M derived: sum of 3 quarters · filed 2026-05-07 | -$4.91M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$2.48M derived: sum of 2 quarters · filed 2026-02-27 | -$3.42M derived: sum of 3 quarters · filed 2026-08-06 | -$4.73M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | -$1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.26M derived: sum of 2 quarters · filed 2026-08-06 | -$3.58M 10-Q · filed 2025-11-06 | -$6.08M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$941.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.25M 10-Q · filed 2026-08-06 | -$4.76M derived: sum of 3 quarters · filed 2026-08-06 | -$5.21M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$1.31M 10-Q · filed 2026-05-07 | -$3.82M derived: sum of 2 quarters · filed 2026-05-07 | -$4.27M derived: sum of 3 quarters · filed 2026-05-07 | -$1.49M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$2.95M derived: sum of 2 quarters · filed 2026-02-27 | -$173.00K derived: sum of 3 quarters · filed 2026-02-27 | -$1.52M 10-K · filed 2026-02-27 | -$2.45M 10-K · filed 2025-02-28 | |||
| 2024-09-30 | -$451.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.33M derived: sum of 2 quarters · filed 2025-11-06 | $980.00K 10-Q · filed 2025-11-06 | $50.00K 10-Q · filed 2024-11-12 | -$2.57M derived: sum of 4 quarters · filed 2026-02-27 | |||
| 2024-06-30 | $2.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.43M 10-Q · filed 2025-08-07 | $1.53M 10-Q · filed 2024-08-09 | -$2.12M derived: sum of 3 quarters · filed 2026-02-27 | -$5.13M derived: sum of 4 quarters · filed 2026-02-27 | |||
| 2024-03-31 | -$1.35M 10-Q · filed 2025-05-07 | -$1.25M 10-Q · filed 2024-05-08 | -$4.90M derived: sum of 2 quarters · filed 2026-02-27 | -$7.91M derived: sum of 3 quarters · filed 2026-02-27 | -$9.23M derived: sum of 4 quarters · filed 2026-02-27 | |||
| 2023-12-31 | -$3.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$6.56M derived: sum of 2 quarters · filed 2026-02-27 | -$7.88M derived: sum of 3 quarters · filed 2026-02-27 | -$9.92M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | -$3.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$4.32M derived: sum of 2 quarters · filed 2024-11-12 | -$6.37M 10-Q · filed 2024-11-12 | -$8.12M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-06-30 | -$1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$3.36M 10-Q · filed 2024-08-09 | -$5.12M derived: sum of 3 quarters · filed 2025-02-28 | -$8.74M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-03-31 | -$2.05M 10-Q · filed 2024-05-08 | -$3.80M derived: sum of 2 quarters · filed 2025-02-28 | -$7.43M derived: sum of 3 quarters · filed 2025-02-28 | -$9.72M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | -$1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$5.38M derived: sum of 2 quarters · filed 2025-02-28 | -$7.67M derived: sum of 3 quarters · filed 2025-02-28 | -$8.83M 10-K · filed 2025-02-28 | ||||
| 2022-09-30 | -$3.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$5.92M derived: sum of 2 quarters · filed 2023-11-09 | -$7.08M 10-Q · filed 2023-11-09 | -$8.74M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-06-30 | -$2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$3.45M 10-Q · filed 2023-08-08 | -$5.12M derived: sum of 3 quarters · filed 2024-03-14 | -$6.32M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-03-31 | -$1.16M 10-Q · filed 2023-05-09 | -$2.82M derived: sum of 2 quarters · filed 2024-03-14 | -$4.02M derived: sum of 3 quarters · filed 2024-03-14 | -$5.36M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-12-31 | -$1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$2.87M derived: sum of 2 quarters · filed 2024-03-14 | -$4.20M derived: sum of 3 quarters · filed 2024-03-14 | -$5.63M 10-K · filed 2024-03-14 | ||||
| 2021-09-30 | -$1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$2.53M derived: sum of 2 quarters · filed 2022-11-07 | -$3.96M 10-Q · filed 2022-11-07 | -$9.54M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-06-30 | -$1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$2.76M 10-Q · filed 2022-08-08 | -$8.33M derived: sum of 3 quarters · filed 2023-03-03 | -$10.43M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-03-31 | -$1.43M 10-Q · filed 2022-05-06 | -$7.00M derived: sum of 2 quarters · filed 2023-03-03 | -$9.09M derived: sum of 3 quarters · filed 2023-03-03 | -$11.98M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2020-12-31 | -$5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -$7.66M derived: sum of 2 quarters · filed 2023-03-03 | -$10.55M derived: sum of 3 quarters · filed 2023-03-03 | -$11.82M 10-K · filed 2023-03-03 | ||||
| 2020-09-30 | -$2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$4.98M derived: sum of 2 quarters · filed 2021-11-08 | -$6.25M 10-Q · filed 2021-11-08 | -$7.61M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | -$2.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$4.16M 10-Q · filed 2021-08-09 | -$5.52M derived: sum of 3 quarters · filed 2022-03-01 | -$8.31M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | -$1.27M 10-Q · filed 2021-05-07 | -$2.63M derived: sum of 2 quarters · filed 2022-03-01 | -$5.42M derived: sum of 3 quarters · filed 2022-03-01 | -$7.47M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | -$1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$4.15M derived: sum of 2 quarters · filed 2022-03-01 | -$6.20M derived: sum of 3 quarters · filed 2022-03-01 | -$7.31M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | -$2.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$4.84M derived: sum of 2 quarters · filed 2020-11-06 | -$5.95M 10-Q · filed 2020-11-06 | -$6.03M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | -$2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$3.15M 10-Q · filed 2020-08-06 | -$3.24M derived: sum of 3 quarters · filed 2021-03-01 | -$362.00K derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | -$1.11M 10-Q · filed 2020-05-11 | -$1.20M derived: sum of 2 quarters · filed 2021-03-01 | $1.68M derived: sum of 3 quarters · filed 2021-03-01 | -$2.67M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | -$89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $2.79M derived: sum of 2 quarters · filed 2021-03-01 | -$1.56M derived: sum of 3 quarters · filed 2021-03-01 | $1.87M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $2.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$1.48M derived: sum of 2 quarters · filed 2019-11-07 | $1.96M 10-Q · filed 2019-11-07 | -$7.55M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | -$4.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$927.00K 10-Q · filed 2019-08-05 | -$934.00K 10-Q · filed 2018-08-09 | -$10.43M derived: sum of 3 quarters · filed 2020-03-02 | -$10.86M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-03-31 | $3.43M 10-Q · filed 2019-05-09 | -$6.07M derived: sum of 2 quarters · filed 2020-03-02 | -$6.50M derived: sum of 3 quarters · filed 2020-03-02 | |||||
| 2017-12-31 | -$9.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$9.94M derived: sum of 2 quarters · filed 2020-03-02 | -$9.94M 10-K · filed 2020-03-02 | |||||
| 2017-09-30 | -$431.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$431.00K 10-Q · filed 2018-11-07 | ||||||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-09 | |||||||
| 2016-12-31 | -$197.00K 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |